He Junli purchased $394K of HRGN
He Junli (CEO) purchased 368,630 shares of Harvard Apparatus Regenerative Technology, Inc. (HRGN) at an average of $1.07 ($1.05–$2.15, $0.39M total) across 2 trades over 2026-09-11 to 2026-09-15.
How this was made
The 30-second read
Why it matters
The filing adds a new data point on insider confidence but is unlikely to move the stock materially.
Market read
Provides a fresh insider transaction record; limited trading relevance.
What to watch
Potential upcoming clinical trial milestones could make the insider's stake more significant.
Background
Form 4 disclosures provide transparent insight into insider transactions. HRGN is a Nasdaq-listed biotech firm.
Ticker impact
CEO He Junli bought 368,630 shares for $394K, increasing his stake to 1.33M shares.
Potential slight upside pressure; limited impact due to small transaction size.
Form 4 filing is primary source; however, the dollar amount is low for a public company, so market reaction likely muted.
Market effects
Minimal; reflects typical insider activity in biotech/medical device sector.
None
Low
Counterpoint
The purchase may be a routine portfolio rebalancing rather than a strong bullish signal.
Key entities
- CompanyHarvard Apparatus Regenerative Technology, Inc.
Issuer of the Form 4 filing.
- PersonHe Junli
CEO and director of HRGN, reported insider purchase.